compare glp 1 drugs GLP-1 Options | Ozempic v Mounjaro | WeightWatchers GLP-1 Drugs Market Size to

Pricing is for a 28-day supply

Recently, the introduction of highly effective glucagon-like peptide-1 (GLP-1) receptor agonists has led to increased utilization of obesity medications in this population

Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in vivo models of neurodegenerative diseases through modulating a variety of pathogenic mechanisms, including neuroinflammation, autophagy, mitochondrial dysfunction, and the abnormal phosphorylation of pathognomonic proteins

Specifically, the trial reported an average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively

Clinical trials, brain mechanisms, and real-world data reveal a complex picture